Alveolus Bio, a cutting-edge respiratory biotech firm founded by Dr. Vivek Lal from the University of Alabama at Birmingham, has secured a strategic financing round led by Raichuru-based Shilpa Medicare.

Known for its strong capabilities in biotechnology and respiratory therapeutics manufacturing, Shilpa Medicare—through its biologics arm, Shilpa Biologics—will serve as Alveolus Bio’s exclusive global development and manufacturing partner.

This collaboration will accelerate the clinical advancement of Alveolus Bio’s novel resMIT (respiratory microbiota-based inhaled therapeutics) platform, which is designed for targeted delivery of inhaled therapies deep into the lungs. The partnership positions Alveolus Bio’s lead COPD asset for upcoming Phase 2 and first-in-human clinical trials, while expanding efforts in diseases such as bronchopulmonary dysplasia and pulmonary fibrosis.

Gaurav Mehta, CEO of Alveolus Bio, hailed the partnership as transformative, emphasizing the synergy between Alveolus’ breakthrough science and Shilpa’s global manufacturing leadership. Dr. C. Vivek Lal, founder and CSO, highlighted the role of the collaboration in speeding up delivery of life-changing therapies to market.

Vishnukant Bhutada, Managing Director of Shilpa Medicare, noted that the agreement enhances Shilpa’s innovation pipeline and cements its position as a global biotech partner. The financing round remains open to additional strategic investors aligned with Alveolus Bio’s mission.